Ohio Moves to Permanently Ban Synthetic Kratom Compounds, Signaling Critical Compliance Shift for Merchants

Ohio Moves to Permanently Ban Synthetic Kratom Compounds, Signaling Critical Compliance Shift for Merchants

COLUMBUS, OH – Ohio is poised to enact a permanent ban on synthetic kratom compounds, a move strongly supported by State Representative Sean Patrick Brennan (D–Parma) and the Joint Committee on Agency Rule Review (JCARR). This decision, which classifies specific synthetic mitragynine-related compounds as Schedule I controlled substances, marks a significant development in the state's approach to kratom regulation and carries substantial implications for merchants and consumers.

The proposed rule from the Ohio Board of Pharmacy, which was scheduled for a JCARR vote on April 13, 2026, aims to permanently prohibit the sale, possession, and distribution of synthetic kratom. This action follows an emergency ban initiated by Governor Mike DeWine in December 2025, which temporarily outlawed synthetic kratom products and is set to expire on June 10, 2026. Importantly, this new rule explicitly exempts natural kratom in its vegetative form, such as kratom leaf or ground natural leaf, from the ban.

Why This Matters to Kratom Merchants and Consumers

This targeted ban is a critical step to safeguard Ohioans from the dangers of highly potent and unpredictable synthetic substances. Lawmakers and public health officials have voiced concerns that synthetic kratom compounds, particularly products with enhanced levels of 7-hydroxymitragynine (7-OH), can be far more potent than natural kratom and are often sold in unregulated environments, making them accessible to minors. The U.S. Food and Drug Administration (FDA) has also raised alarms regarding these synthetic formulations.

For consumers, this means a clearer distinction between natural kratom and potentially harmful synthetic alternatives, promoting greater product safety. For merchants, the impact is immediate and direct: any business currently selling products containing synthetic kratom compounds, including highly concentrated 7-OH extracts, vapes, or gummies marketed as synthetic, must cease these sales in Ohio once the rule is adopted.

While this particular rule focuses on synthetics, it's crucial to acknowledge the ongoing and complex debate surrounding natural kratom in Ohio. The Ohio Board of Pharmacy has also pursued separate rules to classify natural mitragynine as a Schedule I substance, though this has faced significant public and legislative opposition, with efforts underway to instead regulate natural kratom through a Kratom Consumer Protection Act (KCPA). This indicates a dynamic and potentially volatile regulatory landscape for all kratom products in the state.

Compliance Implications for High-Risk Merchants

With the permanent ban on synthetic kratom compounds, compliance becomes paramount. Merchants must understand that specific compounds such as 7-hydroxymitragynine, mitragynine pseudoindoxyl, dihydro-7-hydroxy mitragynine, and 7-acetoxymitragynine will be illegal to sell, possess, or distribute in Ohio. The ability to unequivocally differentiate between natural kratom and these prohibited synthetic or highly concentrated derivatives is no longer just good practice, but a legal necessity.

High-risk merchants in the kratom industry must prioritize robust lab testing and transparency:

• Mandatory Lab Testing and COAs: It is imperative to conduct comprehensive third-party lab testing for every batch of kratom product. Certificates of Analysis (COAs) must be readily available and clearly demonstrate the absence of banned synthetic compounds. These COAs should also verify accurate alkaloid profiles, ensuring that products marketed as natural contain only trace, naturally occurring amounts of 7-OH, not enhanced or synthesized concentrations.
• Accurate Labeling: Product labels must be precise, truthful, and avoid any misleading claims. They should clearly state whether a product is pure natural leaf/powder or an extract, and any potency claims must be directly verifiable by an accompanying COA. Mislabeling could lead to severe legal repercussions.
• Continuous Regulatory Monitoring: The regulatory environment for kratom is constantly evolving. Merchants must stay informed about all legislative developments, including the progress of proposed KCPA bills (like SB 299 and HB 587) and any further rulings from the Ohio Board of Pharmacy.
• Legal Counsel: Given the complexities of state-specific bans and potential for further regulation, consulting legal counsel specializing in dietary supplements or controlled substances is highly recommended to ensure full compliance and mitigate risk.
• Age Verification: Anticipate and prepare for potential age restrictions (e.g., 18 or 21) on natural kratom sales, as these are common components of proposed regulatory frameworks.

This development in Ohio underscores a growing national trend towards distinguishing between natural kratom and its synthetic counterparts. For high-risk merchants, proactive and rigorous compliance measures, centered on transparent lab testing and adherence to evolving regulations, are no longer optional but essential for continued operation.